The incidence of frailty and its relationship with long-term survival in patients with heart failure and implanted cardiac resynchronization therapy devices
https://doi.org/10.15829/1560-4071-2020-3685
Abstract
Aim. To assess long-term survival depending on the presence and severity of frailty in patients with heart failure (HF) and implanted cardiac resynchronization therapy devices.
Material and methods. We examined 77 patients (men — 74%, women — 26%, mean age 58,7±10,7 years) with NYHA class II-IV HF. The follow-up period was 42,4±27,1 months. On the basis of 31 parameters (medical history, diagnostic tests, questionnaire survey of physical activity limitations), a frailty index was calculated. Depending on the index value, the patients were divided into 2 groups: group 1 (n=41) — <0,375 (no frailty), group 2 (n=36) — ≥0,375 (patients with frailty).
Results. Long-term survival of patients in group 1 was 87,8%, in group 2 — 52,8% (Log rank p<0,001). According to the univariate analysis, the presence of frailty was significantly associated with long-term mortality (odds ratio (OR) 6,108; 95% confidence interval (CI) 2,207-16,907; p<0,001). When sex, age, left ventricular ejection fraction, left bundle branch block, QRS duration, left ventricular volume were included in the multivariate analysis, the presence of frailty remained a significant predictor of long-term mortality (OR 5,763; 95% CI 1,837-18,083; p=0,003).
Conclusion. Frailty has an independent effect on the long-term all-cause death risk in patients with HF and implanted cardiac resynchronization therapy devices.
About the Authors
A. M. Soldatova
Tyumen Cardiology Research Center, branch of the Tomsk National Research Medical Center
Russian Federation
Tyumen
Russian Federation
Tyumen
V. A. Kuznetsov
Tyumen Cardiology Research Center, branch of the Tomsk National Research Medical Center
Russian Federation
Tyumen
Russian Federation
Tyumen
D. S. Bogdanova
Tyumen State Medical University
Russian Federation
Tyumen
Russian Federation
Tyumen
F. T. Benzineb
Tyumen State Medical University
Russian Federation
Tyumen
Russian Federation
Tyumen
References
1. Mareev VYu, Fomin IV, Ageev FT, et al. Russian Heart Failure Society, Russian Society of Cardiology. Russian Scientific Medical Society of Internal Medicine Guidelines for Heart failure: chronic (CHF) and acute decompensated (ADHF). Diagnosis, prevention and treatment. Kardiologiia. 2018;58(6S):8-158. (In Russ.) doi:10.18087/cardio.2475.
2. Poole JE, Singh JP, Birgersdotter-Green U. QRS duration or QRS morphology: what really matters in cardiac resynchronization therapy? J Am Coll Cardiol. 2016;67(9):1104-17. doi:10.1016/j.jacc.2015.12.039.
3. Ruwald MH. Co-Morbidities and Cardiac Resynchronization Therapy: When Should They Modify Patient Selection? J Atr Fibrillation. 2015;8(1):1238. doi:10.4022/jafib.1238.
4. Dunlay SM, Park SJ, Joyce LD, et al. Frailty and outcomes after implantation of left ventricular assist device as destination therapy. J Heart Lung Transplant. 2014;33(4):359-65. doi:10.1016/j.healun.2013.12.014.
5. Green P, Arnold SV, Cohen DJ, et al. Relation of frailty to outcomes after transcatheter aortic valve replacement (from the PARTNER trial). Am J Cardiol. 2015;116(2):264-9. doi:10.1016/j.amjcard.2015.03.061.
6. Denfeld QE, Winters-Stone K, Mudd JO, et al. The prevalence of frailty in heart failure: A systematic review and meta-analysis. Int J Cardiol. 2017;236:283-9. doi:10.1016/j.ijcard.2017.01.153.
7. Gastelurrutia P, Lupón J, Altimir S, et al. Fragility is a key determinant of survival in heart failure patients. Int J Cardiol. 2014;175(1):62-6. doi:10.1016/j.ijcard.2014.04.237.
8. Oganov RG, Simanenkov VI, Bakulin IG, et al. Comorbidities in clinical practice. Algorithms for diagnostics and treatment. Cardiovascular Therapy and Prevention. 2019;18(1):5-66. (In Russ.) doi:10.15829/1728-8800-2019-1-5-66.
9. Dent E, Kowal P, Hoogendijk EO. Frailty measurement in research and clinical practice: a review. Eur J Intern Med. 2016;3,1:3-10. doi:10.1016/j.ejim.2016.03.007.
10. Rockwood K, Andrew M, Mitnitski A. A comparison of two approaches to measuring frailty in elderly people. J Gerontol A Biol Sci Med Sci. 2007;62(7):738-43. doi:10.1093/gerona/62.7.738.
11. Dominguez-Rodriguez A, Abreu-Gonzalez P, Jimenez-Sosa A, et al. The impact of frailty in older patients with non-ischaemic cardiomyopathy after implantation of cardiac resynchronization therapy defibrillator. Europace. 2015;17(4):598-602. doi:10.1093/europace/euu333.
12. Mlynarska A, Mlynarski R, Marcisz C, et al. Modified frailty as a novel factor in predicting the response to cardiac resynchronization in the elderly population. Clin Interv Aging. 2019;14:437-43. doi:10.2147/CIA.S193577.
13. Gordon EH, Peel NM, Samanta M, et al. Sex differences in frailty: A systematic review and meta-analysis. Exp Gerontol. 2017;89:30-40. doi:10.1016/j.exger.2016.12.021.
14. Kojima G, Iliffe S, Walters K. Frailty index as a predictor of mortality: a systematic review and meta-analysis. Age Ageing. 2018;47(2):193-200. doi:10.1093/ageing/afx162.
15. Mitnitski A, Howlett SE, Rockwood K. Heterogeneity of Human Aging and Its Assessment. J Gerontol A Biol Sci Med Sci. 2017;72(7):877-84. doi:10.1093/gerona/glw089.
Review
For citations:
Soldatova A.M., Kuznetsov V.A., Bogdanova D.S., Benzineb F.T. The incidence of frailty and its relationship with long-term survival in patients with heart failure and implanted cardiac resynchronization therapy devices. Russian Journal of Cardiology. 2020;25(8):3685. (In Russ.) https://doi.org/10.15829/1560-4071-2020-3685
Views:
535
Email this article 